US7611713B2
(en)
|
1993-03-05 |
2009-11-03 |
Pharmexa Inc. |
Inducing cellular immune responses to hepatitis B virus using peptide compositions
|
US9340577B2
(en)
|
1992-08-07 |
2016-05-17 |
Epimmune Inc. |
HLA binding motifs and peptides and their uses
|
US6291430B1
(en)
|
1997-09-12 |
2001-09-18 |
Ludwig Institute For Cancer Research |
Mage-3 peptides presented by HLA class II molecules
|
US6716809B1
(en)
|
1997-09-12 |
2004-04-06 |
Ludwig Institute For Cancer Research |
Mage-A3 peptides presented by HLA class molecules
|
US6183746B1
(en)
|
1997-10-09 |
2001-02-06 |
Zycos Inc. |
Immunogenic peptides from the HPV E7 protein
|
US6407063B1
(en)
|
1998-10-02 |
2002-06-18 |
Ludwig Institute For Cancer Research |
Tumor antigens and CTL clones isolated by a novel procedure
|
WO2000020445A2
(en)
*
|
1998-10-02 |
2000-04-13 |
Ludwig Institute For Cancer Research |
Tumor antigens and ctl clones isolated by a novel procedure
|
US6541214B1
(en)
*
|
1998-11-13 |
2003-04-01 |
Oregon Heath Science University |
N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
|
GB9826143D0
(en)
*
|
1998-11-27 |
1999-01-20 |
Ludwig Inst Cancer Res |
Tumour rejection antigens
|
WO2000032770A1
(fr)
*
|
1998-12-01 |
2000-06-08 |
Sumitomo Pharmaceuticals Company, Limited |
Nouvelle proteine d'antigene tumoral art-1 et peptide d'antigene tumoral de cette derniere
|
IT1309584B1
(it)
*
|
1999-02-26 |
2002-01-24 |
San Raffaele Centro Fond |
Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
|
AU1440601A
(en)
*
|
1999-10-29 |
2001-05-14 |
Argonex Pharmaceuticals, Inc. |
Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
|
AU1661201A
(en)
*
|
1999-11-18 |
2001-05-30 |
Epimmune, Inc. |
Heteroclitic analogs and related methods
|
CA2393662A1
(en)
*
|
1999-12-10 |
2001-06-14 |
Epimmune Inc. |
Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
|
JP2003517310A
(ja)
*
|
1999-12-10 |
2003-05-27 |
エピミューン, インコーポレイテッド |
ペプチドおよび核酸組成物を使用する、mage2/3に対する細胞性免疫応答の誘導
|
WO2001041787A1
(en)
*
|
1999-12-10 |
2001-06-14 |
Epimmune Inc. |
INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
|
US7026443B1
(en)
*
|
1999-12-10 |
2006-04-11 |
Epimmune Inc. |
Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
|
WO2001045728A2
(en)
*
|
1999-12-21 |
2001-06-28 |
Epimmune Inc. |
Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
|
US7462354B2
(en)
|
1999-12-28 |
2008-12-09 |
Pharmexa Inc. |
Method and system for optimizing minigenes and peptides encoded thereby
|
FR2806727A1
(fr)
*
|
2000-03-23 |
2001-09-28 |
Pf Medicament |
Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
|
WO2001074847A2
(en)
*
|
2000-03-30 |
2001-10-11 |
The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services |
T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
|
CN1107681C
(zh)
*
|
2000-08-11 |
2003-05-07 |
中国科学院微生物研究所 |
乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
|
EP1366153A2
(en)
*
|
2000-08-14 |
2003-12-03 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
|
CA2421448A1
(en)
*
|
2000-09-01 |
2002-03-14 |
Epimmune Inc. |
Hla binding peptides and their uses
|
EP1195381A1
(de)
*
|
2000-09-28 |
2002-04-10 |
Immusystems GmbH |
CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
|
AU3941002A
(en)
|
2000-10-31 |
2002-06-03 |
Zycos Inc |
Cyp1b1 nucleic acids and methods of use
|
WO2002069691A2
(en)
*
|
2001-03-01 |
2002-09-12 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office |
Immunogenic hiv peptides for use as reagents and vaccines
|
CN100589845C
(zh)
*
|
2001-03-07 |
2010-02-17 |
麦康公司 |
用于治疗癌症的抗新血管系统制剂
|
EP1752160A3
(en)
*
|
2001-04-06 |
2007-05-30 |
Mannkind Corporation |
Epitope sequences
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
US20040202654A1
(en)
|
2001-04-09 |
2004-10-14 |
Mayo Foundation For Medical Education & Research |
Methods and materials for cancer treatment
|
US7842480B2
(en)
|
2001-05-18 |
2010-11-30 |
Mayo Foundation For Medical Education And Research |
Chimeric antigen-specific t cell-activating polypeptides
|
US7049413B2
(en)
|
2001-05-18 |
2006-05-23 |
Ludwig Institute For Cancer Research |
MAGE-A3 peptides presented by HLA class II molecules
|
US20060222656A1
(en)
|
2005-04-01 |
2006-10-05 |
University Of Maryland, Baltimore |
MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
|
WO2002099039A2
(en)
*
|
2001-06-05 |
2002-12-12 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services, Centers For Disease Control And Prevention |
Peptides for chlamydophila pneumoniae vaccine and diagnosis
|
US20030113919A1
(en)
*
|
2001-08-17 |
2003-06-19 |
Aventis Pasteur, Ltd. |
Immunogenic targets for melanoma
|
CA2357906A1
(en)
|
2001-09-28 |
2003-03-28 |
Institut Pasteur |
Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
|
EP2314712B1
(en)
|
2001-11-07 |
2014-01-08 |
Mannkind Corporation |
Expression vectors encoding epitopes of antigens and methods for their design
|
WO2003050140A1
(fr)
*
|
2001-12-10 |
2003-06-19 |
Kyogo Itoh |
Antigenes tumoraux
|
CA2481462A1
(en)
*
|
2002-04-05 |
2003-10-23 |
Epimmune Inc. |
Heteroclitic analogs and related methods
|
DK1587837T3
(da)
|
2003-01-28 |
2012-09-24 |
Proscan Rx Pharma Inc |
Epitopsekvenser til diagnose og behandling af prostatacancer
|
JPWO2005007694A1
(ja)
*
|
2003-07-16 |
2007-09-20 |
株式会社グリーンペプタイド |
HER2/neuペプチドおよびその治療上の用途
|
CA2537900A1
(en)
*
|
2003-09-03 |
2005-04-28 |
Dendritherapeutics, Inc. |
Multiplex vaccines
|
EP2267004A3
(en)
*
|
2003-09-22 |
2011-04-27 |
Green Peptide Co., Ltd. |
Peptide derived from hepatitis C virus
|
US7488793B2
(en)
*
|
2003-09-22 |
2009-02-10 |
Ludwig Institute For Cancer Research |
Isolated peptide which binds to HLA-Cw*07 and uses thereof
|
US9090673B2
(en)
*
|
2003-12-12 |
2015-07-28 |
City Of Hope |
Synthetic conjugate of CpG DNA and T-help/CTL peptide
|
GB0716992D0
(en)
|
2007-08-31 |
2007-10-10 |
Immune Targeting Systems Its L |
Influenza antigen delivery vectors and constructs
|
GB0408164D0
(en)
|
2004-04-13 |
2004-05-19 |
Immune Targeting Systems Ltd |
Antigen delivery vectors and constructs
|
WO2005103679A2
(en)
|
2004-04-21 |
2005-11-03 |
Algonomics Nv |
Method for affinity scoring of peptide/protein complexes
|
EP2559763B1
(en)
*
|
2004-04-30 |
2017-02-15 |
NEC Corporation |
HLA-binding peptides, precursors thereof, DNA fragments and recombinant vectors that code for those peptide sequences
|
JP5176099B2
(ja)
*
|
2004-09-27 |
2013-04-03 |
国立大学法人 東京医科歯科大学 |
HLA−A11拘束性Tax抗腫瘍エピトープ
|
US20080306243A1
(en)
*
|
2005-09-07 |
2008-12-11 |
Nec Corporation |
Hla-Binding Peptide, and Dna Fragment and Recombinant Vector Coding for Said Hla-Binding Peptide
|
EP2016095A2
(en)
|
2006-04-13 |
2009-01-21 |
Peptimmune, Inc. |
Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
|
WO2008010010A1
(en)
*
|
2006-07-12 |
2008-01-24 |
Vaxon Biotech |
Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
|
AU2008311897B2
(en)
|
2007-10-16 |
2015-03-26 |
Declion Holdings Llc |
Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
|
EP2249857A4
(en)
*
|
2008-01-18 |
2012-02-29 |
Aeras Global Tb Vaccine Foundation |
MALARIA VACCINE COMPOSITIONS AND COMPONENTS THAT INDUCE CELL MEDIATION IMMUNITY
|
WO2010086294A2
(en)
|
2009-01-28 |
2010-08-05 |
Epimmune Inc. |
Pan-dr binding polypeptides and uses thereof
|
JP2013506682A
(ja)
*
|
2009-09-30 |
2013-02-28 |
セント ルイス ユニバーシティ |
異種亜型インフルエンザt細胞応答を誘発するためのペプチド
|
WO2012033142A1
(ja)
|
2010-09-08 |
2012-03-15 |
学校法人 埼玉医科大学 |
C型肝炎ウイルスリポソームワクチン
|
CA2830349C
(en)
|
2011-03-17 |
2019-07-16 |
The University Of Birmingham |
Re-directed immunotherapy
|
EP3444262A3
(en)
*
|
2011-09-09 |
2019-04-10 |
Agency For Science, Technology And Research |
P53 activating peptides
|
CN104136040B
(zh)
*
|
2012-01-20 |
2021-05-25 |
费尔南多·托姆·克罗伊茨 |
自体癌细胞疫苗
|
JP5999703B2
(ja)
*
|
2013-01-09 |
2016-09-28 |
国立大学法人 東京医科歯科大学 |
HLA−DR1拘束性Tax特異的CD4+T細胞エピトープ
|
CA2975439A1
(en)
*
|
2015-02-18 |
2016-08-25 |
F.Hoffmann-La Roche Ag |
Immunoconjugates for specific induction of t cell cytotoxicity against a target cell
|
CN105037559B
(zh)
*
|
2015-08-17 |
2018-09-25 |
北京康爱瑞浩生物科技股份有限公司 |
治疗或预防乙肝的细胞毒性t淋巴细胞及其制备方法
|
TWI782434B
(zh)
|
2015-08-28 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
|
GB201515321D0
(en)
*
|
2015-08-28 |
2015-10-14 |
Immatics Biotechnologies Gmbh |
Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
|
US11111277B2
(en)
|
2016-12-28 |
2021-09-07 |
Invvax, Inc. |
Influenza vaccines
|
AU2018326805B2
(en)
|
2017-09-01 |
2023-11-30 |
Dana-Farber Cancer Institute, Inc. |
Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer
|
EP3545967A1
(en)
*
|
2018-03-28 |
2019-10-02 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Cancer immunization platform
|
US20230087348A1
(en)
*
|
2019-01-11 |
2023-03-23 |
Agency For Science, Technology And Research |
Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells
|
KR20210144739A
(ko)
*
|
2019-03-04 |
2021-11-30 |
유니버시티 헬스 네트워크 |
T 세포 수용체 및 이의 사용 방법
|